NDA 208351 · Gilead Sciences INC
Odefsey
Emtricitabine, Rilpivirine Hydrochloride, Tenofovir Alafenamide Fumarate · Oral · Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Priority reviewLast checked: Nov 19, 2026Latest source record: Feb 19, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2016
Mar 1, 2016
Approved uses
7
Original approval plus efficacy supplements
Registered trials
684
198 Phase 3, 28 recruiting
FAERS reports
3,596
2,736 serious, 72 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B Severe acute exacerbations of hepatitis B have been reported in patients with HIV-1 and HBV who have discontinued products containing emtricitabine (FTC) and/or tenofovir disoproxil fumarate (TDF), and may occur with discontinuation of ODEFSEY. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients with HIV-1 and HBV who discontinue ODEFSEY. If appropriate, anti-hepatitis B therapy may be warranted [see Warnings and Precautions (5.1) ] . WARNING: POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B See full prescribing information for complete boxed warning. Severe acute exacerbations of hepatitis B have been reported in patients with HIV-1 and HBV who have discontinued products containing emtricitabine (FTC) and/or tenofovir disoproxil fumarate (TDF), and may...
What it is approved for
From the label in effect Dec 2, 2025.
ODEFSEY is indicated as a complete regimen for the treatment of HIV-1 infection in adult and pediatric patients weighing at least 25 kg: as initial therapy in those with no antiretroviral treatment history with HIV-1 RNA less than or equal to 100,000 copies/mL or to replace a stable antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies/mL) for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of ODEFSEY [see Microbiology (12.4) and Clinical Studies (14) ]. ODEFSEY is a three-drug combination of emtricitabine (FTC) and tenofovir alafenamide (TAF), both HIV nucleoside analog reverse transcriptase inhibitors (NRTIs), and rilpivirine (RPV), a non-nucleoside reverse transcriptase inhibitor (NNRTI), and is indicated as a complete regimen for the treatment of HIV-1 infection in adult and pediatric patients weighing at least 25kg: as initial therapy in those with no antiretroviral treatment history with HIV-1 RNA less than or equal to 100,000 copies/mL; or to replace a stable antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies/mL) for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of ODEFSEY. ( 1 ) Limitations of Use : More rilpivirine-treated participants with HIV-1 RNA greater than 100,000 copies/mL at the start of therapy experienced virologic failure (HIV-1 RNA ≥ 50 copies/mL) compared to rilpivirine-treated participants with HIV-1 RNA less than or equal to 100,000 copies/mL. ( 14.2 , 14.3 ) Limitations of Use: More rilpivirine-treated participants with no antiretroviral treatment history with HIV-1 RNA greater...
Mechanism: ODEFSEY is a fixed dose combination of antiretroviral drugs emtricitabine, rilpivirine, and tenofovir alafenamide [see Microbiology (12.4) ] .
Therapeutic areas: Infectious disease and vaccines · Rare and genetic disease
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 19, 2025 Supplement 15 · Efficacy LabelLetter
- Feb 19, 2025 Supplement 14 · Efficacy LabelLetter
- Dec 3, 2019 Supplement 10 · Efficacy LetterLabel
- Oct 31, 2018 Supplement 6 · Efficacy LetterLabel
- Aug 21, 2017 Supplement 2 · Efficacy LabelLetter
- Aug 21, 2017 Supplement 3 · Efficacy LabelLetter
- Mar 1, 2016 Original approval · Type 4 - New Combination · priority review ReviewPediatric Medical ReviewPediatric CDTL Review
1 products under this application
- ODEFSEY · EMTRICITABINE 200MG; RILPIVIRINE HYDROCHLORIDE EQ 25MG BASE; TENOFOVIR ALAFENAMIDE FUMARATE EQ 25MG BASE · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Emtricitabine" as an intervention, any sponsor and status, largest first.
- Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV IncidencePivotal-lookingCompleted
ANRS, Emerging Infectious DiseasesGovernment (non-federal)
NCT01509508 · 28,153 participants · Start Mar 2012 · Primary completion Jun 2016
Drug: Immediate ARV treatment initiation with TDF/FTC/EFV · For: HIV Infection
Sites: Hlabisa, South Africa
University of WashingtonAcademic, hospital or other
NCT04666792 · 25,457 participants · Start Mar 1, 2021 · Primary completion Dec 31, 2024
Drug: PrEP · For: HIV Infections; Contraception; STI
Sites: Kisumu, Kenya
- Expanded PrEP Implementation in Communities in NSWPivotal-lookingCompleted
Kirby InstituteGovernment (non-federal)
NCT02870790 · 9,733 participants · Start Mar 2016 · Primary completion Mar 2019
Drug: TDF/FTC · For: HIV; STI
Sites: Canberra, Australia; Albury, Australia; Alexandria, Australia · 31 sites in all
Gilead SciencesGilead Sciences (GILD)
NCT02842086 · 5,399 participants · Start Sep 2, 2016 · Primary completion Jan 31, 2019
Drug: F/TAF; F/TDF and 2 more · For: Pre-Exposure Prophylaxis of HIV-1 Infection
Sites: Beverly Hills, California; Los Angeles, California; Newport Beach, California · 93 sites in all
- Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV InfectionPivotal-lookingActive, not recruiting
Gilead SciencesGilead Sciences (GILD)
NCT04994509 · 5,368 participants · Start Aug 30, 2021 · Primary completion May 27, 2024
Drug: Oral Lenacapavir (LEN); Subcutaneous (SC) Lenacapavir (LEN) and 6 more · For: Pre-Exposure Prophylaxis of HIV Infection
Sites: Brits, South Africa; Cape Town, South Africa; Durban, South Africa · 28 sites in all
- Safety and Effectiveness of TFV 1% Gel, TDF Tablets, and FTC/TDF Tablets in Preventing HIV in WomenPivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00705679 · 5,029 participants · Start Aug 2009 · Primary completion Aug 2012
Drug: Emtricitabine/tenofovir disoproxil fumarate; Emtricitabine/tenofovir disoproxil fumarate placebo and 4 more · For: HIV Infections
Sites: Johannesburg, South Africa; Asherville, South Africa; Chatsworth, South Africa · 15 sites in all
- The Partners Scale-Up ProjectCompleted
University of WashingtonAcademic, hospital or other
NCT03052010 · 4,898 participants · Start Feb 6, 2017 · Primary completion Dec 15, 2020
Drug: PrEP; ART · For: HIV-1-infection
Sites: Kisumu, Kenya; Thika, Kenya
- Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition Within HIV-1 Discordant CouplesPivotal-lookingCompleted
University of WashingtonAcademic, hospital or other
NCT00557245 · 4,758 participants · Start May 2008 · Primary completion Oct 2013
Drug: Tenofovir Disoproxil Fumarate (TDF); Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) and 1 more · For: HIV-1 Infections; HIV Infections
Sites: Eldoret, Kenya; Kisumu, Kenya; Nairobi, Kenya · 9 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- bone density decreased1,605
- chronic kidney disease874
- tooth loss822
- osteoporosis758
- bone loss748
- osteonecrosis713
- pain711
- emotional distress692
- multiple fractures691
- renal failure650
- anxiety645
- anhedonia604
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2016 | 52 |
| 2017 | 119 |
| 2018 | 224 |
| 2019 | 379 |
| 2020 | 1,378 |
| 2021 | 542 |
| 2022 | 342 |
| 2023 | 176 |
| 2024 | 183 |
| 2025 | 143 |
| 2026 | 58 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Odefsey (Emtricitab/Rilpiviri/Tenof Ala)
2024 spending
$375M
Beneficiaries
10,329
97,021 claims
Per beneficiary
$36,352
$119.20 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $358,188,117 |
| 2021 | $361,085,877 |
| 2022 | $371,681,940 |
| 2023 | $383,667,795 |
| 2024 | $375,477,600 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women.
Bekker LG, Das M, Abdool Karim Q, et al. · N Engl J Med 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
- Oral pre-exposure prophylaxis (PrEP) to prevent HIV: a systematic review and meta-analysis of clinical effectiveness, safety, adherence and risk compensation in all populations.
O Murchu E, Marshall L, Teljeur C, et al. · BMJ Open 2022 · Meta-Analysis, Systematic Review
- Safety and Efficacy of Long-Acting Injectable Agents for HIV-1: Systematic Review and Meta-Analysis.
Wang W, Zhao S, Wu Y, et al. · JMIR Public Health Surveill 2023 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial.
Ramgopal MN, Castagna A, Cazanave C, et al. · Lancet HIV 2023 · Randomized Controlled Trial, Multicenter Study
- Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
Mayer KH, Molina JM, Thompson MA, et al. · Lancet 2020 · Clinical Trial, Phase III, Comparative Study
- Efficacy and safety of antiviral prophylaxis during pregnancy to prevent mother-to-child transmission of hepatitis B virus: a systematic review and meta-analysis.
Funk AL, Lu Y, Yoshida K, et al. · Lancet Infect Dis 2021 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Gilead Sciences
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.